×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BYSI – beyondspring, inc. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BYSI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/11
08:00 am
bysi
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Low
Report
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
9/16
05:48 pm
bysi
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC [Seeking Alpha]
Low
Report
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC [Seeking Alpha]
9/16
07:12 am
bysi
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 [Yahoo! Finance]
Medium
Report
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 [Yahoo! Finance]
9/16
07:00 am
bysi
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
Medium
Report
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
9/16
07:00 am
bysi
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
Medium
Report
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
9/10
07:00 am
bysi
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medic
Medium
Report
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medic
9/3
07:00 am
bysi
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
Medium
Report
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
8/31
09:02 am
bysi
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? [Yahoo! Finance]
Medium
Report
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
09:53 pm
bysi
Form SC 13G/A BeyondSpring Inc. Filed by: Decheng Capital Management III (Cayman), LLC
Medium
Report
Form SC 13G/A BeyondSpring Inc. Filed by: Decheng Capital Management III (Cayman), LLC
8/29
04:31 pm
bysi
Form 6-K BeyondSpring Inc. For: Jun 30
Medium
Report
Form 6-K BeyondSpring Inc. For: Jun 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Beyondspring Inc (NASDAQ: BYSI) had its "buy" rating re-affirmed by analysts at William Blair.
22.2%
9/6 BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference 19.2%
4/28 Beyondspring Inc (NASDAQ: BYSI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.8%
1/10 Beyondspring Inc (NASDAQ: BYSI) is now covered by analysts at Nomura. They set a "buy" rating and a $34.00 price target on the stock. 11.3%
12/9 BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting 4.4%
9/10 BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer 4.3%
5/16 BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting 4.2%
12/19 BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies 3.4%
10/23 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock. 3.1%
9/11 BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019 2.7%
9/6 BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference 19.2%
4/28 Beyondspring Inc (NASDAQ: BYSI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.8%
1/10 Beyondspring Inc (NASDAQ: BYSI) is now covered by analysts at Nomura. They set a "buy" rating and a $34.00 price target on the stock. 11.3%
12/9 BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting 4.4%
9/10 BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer 4.3%
5/16 BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting 4.2%
12/19 BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies 3.4%
10/23 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock. 3.1%
9/11 BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019 2.7%
TOP News Decliners
10/24
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
-26.8%
2/10 BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients -19.4%
7/16 BeyondSpring Announces Proposed Public Offering of Ordinary Shares -10.4%
3/11 Form 6-K BeyondSpring Inc. For: Mar 11 -8.7%
4/30 Form 20-F BeyondSpring Inc. For: Dec 31 -8.6%
3/11 BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 -8.1%
5/21 Form 424B5 BeyondSpring Inc. -6.8%
4/20 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -6.1%
10/23 BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia -5.2%
8/23 BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia -5.0%
2/10 BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients -19.4%
7/16 BeyondSpring Announces Proposed Public Offering of Ordinary Shares -10.4%
3/11 Form 6-K BeyondSpring Inc. For: Mar 11 -8.7%
4/30 Form 20-F BeyondSpring Inc. For: Dec 31 -8.6%
3/11 BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 -8.1%
5/21 Form 424B5 BeyondSpring Inc. -6.8%
4/20 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -6.1%
10/23 BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia -5.2%
8/23 BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: